|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||86.77 - 87.75|
|52 Week Range||55.06 - 89.69|
|PE Ratio (TTM)||21.52|
|Dividend & Yield||2.56 (2.96%)|
|1y Target Est||N/A|
Expiring patents present the company with challenges, yet management thinks it has the right strategy in place to navigate this threat.
Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.
Leaves might fall in autumn, but these big biotech stocks should rise.